1-4 of 4
Jordan S. Fridman, PhD
Close
Sort by
Journal Articles

FLX925 Is a Rationally Designed FLT3, CDK4/6 Inhibitor with a Desirable Resistance Profile

Sachie Marubayashi, M.S., Adam Park, B.S., Rajkumar Noubade, PhD, Huyen Phan, B.S., Gene Cutler, PhD, Paul Kassner, PhD, Jordan S Fridman, PhD
Journal: Blood
Blood (2016) 128 (22): 2323.
https://doi.org/10.1182/blood.V128.22.2323.2323
Published: 2016
Journal Articles

A Machine-Learning Analysis Suggests That FLX925, a FLT3/CDK4/6 Kinase Inhibitor, Is Potent Against FLT3-Wild Type Tumors Via Its CDK4/6 Activity

Gene Cutler, PhD, Jordan S Fridman, PhD
Journal: Blood
Blood (2016) 128 (22): 3520.
https://doi.org/10.1182/blood.V128.22.3520.3520
Published: 2016
Journal Articles

The JAK Inhibitor INCB20 Induces Antiproliferative and Apoptotic Effects in Human Myeloma Cells In Vitro and In Vivo .

Renate Burger, PhD, Steven Legouill, MD, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Klaus Podar, MD, PhD, Laurence Catley, MD, Pierfrancesco Tassone, MD, Paola Neri, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Eian Caulder, BS, Kris Vaddi, PhD, Claire L. Neilan, PhD, Martin Gramatzki, MD, Jordan S. Fridman, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2005) 106 (11): 3357.
https://doi.org/10.1182/blood.V106.11.3357.3357
Published: 2005
Journal Articles

Inhibition of Human Plasmacytoma Cell Growth by a Novel JAK Kinase Inhibitor.

Renate Burger, PhD, Steven Legouill, MD, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Klaus Podar, MD, PhD, Laurence Catley, MD, Pierfrancesco Tassone, MD, Paola Neri, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Jordan S. Fridman, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2004) 104 (11): 644.
https://doi.org/10.1182/blood.V104.11.644.644
Published: 2004